Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Abivax S.A. ABVX NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • FR • USD

SharesGrow Score
59/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$145.67
+15.8%

Abivax S.A. (ABVX) is a Biotechnology company in the Healthcare sector, currently trading at $125.80. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ABVX = $146 (+15.8% upside).

Valuation: ABVX trades at a trailing Price-to-Earnings (P/E) of -21.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.16.

Net income is $323M (loss), growing at -81.9%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+2.4 pp trend).

Balance sheet: total debt is $32M against $455M equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 8.75 (strong liquidity). Debt-to-assets is 5.5%. Total assets: $584M.

Analyst outlook: 9 / 9 analysts rate ABVX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 83/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 62/100 (Partial), Future 94/100 (Pass), Income ?/100 (Fail).

$145.67
▲ 15.79% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Abivax S.A., the average price target is $145.67, with a high forecast of $176.00, and a low forecast of $110.00.
Highest Price Target
$176.00
Average Price Target
$145.67
Lowest Price Target
$110.00

ABVX SharesGrow Score Overview

71/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 83/100
Valuation — P/E, PEG, Forward PEG
GROWTH 48/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 62/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ABVX

✓
VALUE Pass
83/100
ABVX trades at a trailing Price-to-Earnings (P/E) of -21.4 (S&P 500 average ~25). Forward PEG 1.16 — ~moderate (~1.5). Trailing PEG 0.38. Analyst consensus target is $146, implying +16.1% from the current price $126. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
48/100
ABVX: +11.5%/yr revenue is, -81.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ABVX: Debt-to-Equity (D/E) ratio 0.07 (conservative), Current ratio is 8.75 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
62/100
ABVX: Gross margin is 100% (+2.4 pp trend), $8B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 62/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 9 / 9 analysts rate ABVX as buy (100%). Analyst consensus target is $146 (+16.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range4.77-148.83
Volume934.17K
Avg Volume (30D)989.46K
Market Cap$8.25B
Beta (1Y)-0.10
Share Statistics
EPS (TTM)-4.65
Shares Outstanding$69.53M
IPO Date2023-10-20
Employees69
CEODidier Blondel
Financial Highlights & Ratios
Gross Profit$-1.03M
EBITDA$-239.7M
Net Income$-322.84M
Operating Income$-240.73M
Total Cash$530.16M
Total Debt$32.08M
Net Debt$-484.39M
Total Assets$584.09M
Price / Earnings (P/E)-27.1
Analyst Forecast
1Y Price Target$142.00
Target High$176.00
Target Low$110.00
Upside+12.9%
Rating ConsensusBuy
Analysts Covering9
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryFR
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS00370M1036

Price Chart

Track all markets on TradingView
ABVX
Abivax S.A. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
4.77 52WK RANGE 148.83

People Also View

JAZZ
JAZZ
Jazz Pharmaceuticals plc
$201.06
+2.94%
 MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 AXSM
AXSM
Axsome Therapeutics, Inc.
$184.18
+3.28%
 CYTK
CYTK
Cytokinetics, Incorporated
$66.35
-0.55%
 HALO
HALO
Halozyme Therapeutics, Inc.
$67.31
+0.49%
 NUVL
NUVL
Nuvalent, Inc.
$105.02
+1.28%
 MTSR
MTSR
Metsera, Inc.
$70.50
-0.35%
 MRUS
MRUS
Merus N.V.
$90.00
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message